Obsidian Therapeutics, Inc. (OBX) stock
OBXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$12.00−0.15 (-1.23%)
Close on Nov 20, 2026Market cap $741.28MP/E –Yield –
Obsidian Therapeutics cash
Cash and short-term investments held at the end of each period.
Obsidian Therapeutics's cash was $324.40M at Sep 30, 2026. For fiscal 2025 it was $80.50M, up 58.6% from the year before.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $80.50M | +58.6% |
| FY2024 | Dec 31, 2024 | $50.77M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $324.40M | +768.2% |
| Q2 FY2026 | Jun 30, 2026 | $0 | -100.0% |
| Q1 FY2026 | Apr 10, 2026 | $0 | – |
| Q4 FY2025 | Dec 31, 2025 | $80.50M | – |
| Q3 FY2025 | Sep 30, 2025 | $37.36M | – |
| Q4 FY2024 | Dec 31, 2024 | $50.77M | – |
See a number that looks wrong?